79 related articles for article (PubMed ID: 28137814)
1. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
van Rijn SP; Zuur MA; van Altena R; Akkerman OW; Proost JH; de Lange WC; Kerstjens HA; Touw DJ; van der Werf TS; Kosterink JG; Alffenaar JW
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137814
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.
van den Elsen SHJ; Sturkenboom MGG; Van't Boveneind-Vrubleuskaya N; Skrahina A; van der Werf TS; Heysell SK; Mpagama S; Migliori GB; Peloquin CA; Touw DJ; Alffenaar JC
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30373800
[TBL] [Abstract][Full Text] [Related]
3. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.
Alsultan A; An G; Peloquin CA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3800-7. PubMed ID: 25870068
[TBL] [Abstract][Full Text] [Related]
4. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
[TBL] [Abstract][Full Text] [Related]
5. d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.
Deshpande D; Alffenaar JC; Köser CU; Dheda K; Chapagain ML; Simbar N; Schön T; Sturkenboom MGG; McIlleron H; Lee PS; Koeuth T; Mpagama SG; Banu S; Foongladda S; Ogarkov O; Pholwat S; Houpt ER; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S308-S316. PubMed ID: 30496460
[TBL] [Abstract][Full Text] [Related]
6. Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant
Singh S; Gumbo T; Boorgula GD; Thomas TA; Philley JV; Srivastava S
Antimicrob Agents Chemother; 2024 Feb; 68(2):e0108023. PubMed ID: 38131673
[TBL] [Abstract][Full Text] [Related]
7. Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Mpagama SG; Bendet P; Srivastava S; Koeuth T; Lee PS; Bhavnani SM; Ambrose PG; Thwaites G; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S293-S302. PubMed ID: 30496461
[TBL] [Abstract][Full Text] [Related]
8. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.
Vu DH; Bolhuis MS; Koster RA; Greijdanus B; de Lange WC; van Altena R; Brouwers JR; Uges DR; Alffenaar JW
Antimicrob Agents Chemother; 2012 Nov; 56(11):5758-63. PubMed ID: 22926568
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
Zhu Y; Zhu L; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Xiong H; Alffenaar JW; Hu Y
Antimicrob Agents Chemother; 2023 May; 67(5):e0170022. PubMed ID: 37097151
[TBL] [Abstract][Full Text] [Related]
10. Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.
Musuka S; Srivastava S; Siyambalapitiyage Dona CW; Meek C; Leff R; Pasipanodya J; Gumbo T
Antimicrob Agents Chemother; 2013 Dec; 57(12):5870-7. PubMed ID: 24041886
[TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.
Zvada SP; Denti P; Sirgel FA; Chigutsa E; Hatherill M; Charalambous S; Mungofa S; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
Antimicrob Agents Chemother; 2014; 58(1):503-10. PubMed ID: 24189253
[TBL] [Abstract][Full Text] [Related]
12. Limited sampling strategies for therapeutic drug monitoring of anti-tuberculosis medications: A systematic review of their feasibility and clinical utility.
Xavier RM; Sharumathi SM; Kanniyappan Parthasarathy A; Mani D; Mohanasundaram T
Tuberculosis (Edinb); 2023 Jul; 141():102367. PubMed ID: 37429151
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs.
Garcia-Contreras L; Muttil P; Fallon JK; Kabadi M; Gerety R; Hickey AJ
Antimicrob Agents Chemother; 2012 May; 56(5):2612-8. PubMed ID: 22330920
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone.
Chirehwa MT; Court R; de Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Maartens G; Warren R; Denti P; McIlleron H
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816738
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.
Chigutsa E; Meredith S; Wiesner L; Padayatchi N; Harding J; Moodley P; Mac Kenzie WR; Weiner M; McIlleron H; Kirkpatrick CM
Antimicrob Agents Chemother; 2012 Jul; 56(7):3857-63. PubMed ID: 22564839
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.
Mase SR; Jereb JA; Gonzalez D; Martin F; Daley CL; Fred D; Loeffler AM; Menon LR; Bamrah Morris S; Brostrom R; Chorba T; Peloquin CA
Pediatr Infect Dis J; 2016 Apr; 35(4):414-21. PubMed ID: 26658531
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics and Limited Sampling Strategy for Therapeutic Drug Monitoring of Polymyxin B in Chinese Patients With Multidrug-Resistant Gram-Negative Bacterial Infections.
Wang P; Zhang Q; Zhu Z; Feng M; Sun T; Yang J; Zhang X
Front Pharmacol; 2020; 11():829. PubMed ID: 32581795
[TBL] [Abstract][Full Text] [Related]
18. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
van der Laan LE; Garcia-Prats AJ; McIlleron H; Abdelwahab MT; Winckler JL; Draper HR; Wiesner L; Schaaf HS; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0061123. PubMed ID: 37971239
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.
Gumbo T; Alffenaar JC
Clin Infect Dis; 2018 Nov; 67(suppl_3):S267-S273. PubMed ID: 30496455
[TBL] [Abstract][Full Text] [Related]
20. Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fiber model.
Deshpande D; Srivastava S; Gumbo T
Int J Antimicrob Agents; 2024 May; ():107204. PubMed ID: 38754528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
